|
|
|
|
|
|
|
|
|
|
Previous: ALEXION PHARMACEUTICALS INC, 10-Q, EX-10.2, 2000-06-13 |
Next: HUMAN GENOME SCIENCES INC, 424B3, 2000-06-13 |
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE BALANCE
SHEET, THE STATEMENT OF OPERATIONS, AND THE STATEMENT OF CASH FLOWS AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> JUL-31-2000
<PERIOD-START> AUG-01-1999
<PERIOD-END> APR-30-2000
<CASH> 168,764
<SECURITIES> 6,766
<RECEIVABLES> 5,648
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 181,751
<PP&E> 12,859
<DEPRECIATION> (4,365)
<TOTAL-ASSETS> 194,939
<CURRENT-LIABILITIES> 4,893
<BONDS> 124,106
0
0
<COMMON> 2
<OTHER-SE> 65,940
<TOTAL-LIABILITY-AND-EQUITY> 194,939
<SALES> 0
<TOTAL-REVENUES> 17,450
<CGS> 0
<TOTAL-COSTS> 34,379
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 1,794
<INCOME-PRETAX> (15,135)
<INCOME-TAX> 0
<INCOME-CONTINUING> (15,135)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (15,135)
<EPS-BASIC> (1.11)
<EPS-DILUTED> (1.11)
</TABLE>
|
|